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Summary.-A reduced response of a tumour to chemotherapy may be due to the
host's drug metabolism. To test this hypothesis, we measured the metabolism of
a model drug, para-aminosalicylate (PAS). Volunteers and cancer patients in-
gested a single oral dose (2 g) of PAS and we measured the plasma disappearance
curve of the drug and its metabolite. In 7 patients suffering from lymphosarcoma,
acute or chronic leukaemia and resistant to cancer chemotherapy, we observed low
plasma PAS concentrations, an increase in PAS acetylation and an increased number
(and a higher frequency) of abnormal liver-function tests. In 14 patients with
malignant blood disease, yet responding well to chemotherapy, the metabolism of
PAS is similar to that of healthy controls of the same age and sex. The plasma
half-life of PAS is similar in sensitive and resistant patients, but slightly longer
than in volunteers. Finally, in urine collected 120 min after drug administration,
we observed the same results as in plasma. In conclusion, cancer patients resistant
to chemotherapy do not metabolize the model drug PAS as volunteers or sensitive
patients do, and this might be relevant to the terminal stage of the disease.
CLINICAL resistance to cancer chemo-
therapy still constitutes a major problem
in the use of therapeutic agents (Lane,
1974). Inadequate response to treatment
might be explained by, among many
mechanisms, altered kinetics of antineo-
plastic drugs (Connors, 1974; Dedrick et
al., 1975; Lavigne, 1976).
On the other hand, many studies
have shown the non-specific influence
ofmalignant diseases on drug metabolism.
Indeed, the presence of cancer modifies
the pharmacokinetics of several drugs
with or without antineoplastic properties.
Moreover, it is known that the activity
of the hepatic enzymes responsible for
drug oxidation, reduction, hydrolysis
(Phase I drug reactions) and conjugation
(Phase II drug reactions) are unspecifically
influenced by, for example, a disease
or a drug metabolism inducer or inhibitor
(Bousquet, 1970).
Consequently, we decided to measure
the in vivo metabolism of a model drug,
para-aminosalicylate (PAS), in patients
suffering from malignant blood disease
and sensitive or resistant to cancer
chemotherapy. The purpose of the pre-
sent study was to investigate the possible
relationship between the degree of re-
sistance to cancer chemotherapy and
the pharmacokinetics of our model drug,
with reference to some tests of liver
function.
MATERIALS AND METHODS
Control and test subjects.-Group I: 9
healthy volunteers of either sex, 25 to 74
years old, having normal hepatic and renal
functions. Group II: 14 patients of either
sex, 18 to 83 years old, suffering from
malignant blood disease (lymphosarcoma,
LSCL, AML, CML, CLL) and responding
well to cancer chemotherapy. Group III:
7 patients of either sex, 47 to 69 years old,
originally in Group II, who later became
resistant to cancer chemotherapy and died.
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are those obtained 30 to 90 days before
death
Drug administration.-Volunteers and pa-
tients were asked to abstain from foods
and drugs for 12 h preceding drug adminis-
tration. They ingested, with 100 ml of
water, 4 gelatin capsules, each containing
500 mg ofsodium para-aminosalicylate PAS).
A catheter (" Butterfly-21 ") was inserted
in a vein of the forearm, and blood samples
(5 ml) were taken at 10, 30, 60 and 120 min
after PAS administration (plus one sample
taken before PAS). Between each sampling,
0 3 ml of heparin (1000 u/ml) was introduced
in the catheter to prevent blood coagulation.
Urine was collected at the end of the test.
Assay for PAS and APAS.-PAS was
measured in plasma and urine according
to the method described by Bratton and
Marshall (1939) as modified by Way et al.
(1948). N-acetyl-para-aminosalicylic acid
(APAS), the main conjugated metabolite
of PAS, was measured in plasma and urine
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using the technique ofWan, Pentikaenen and
Azarnoff (1974).
Plasma half-life ofPAS.-Plasma half-life
(T1/2) of unchanged p-aminosalicylate (PAS)
was calculated from the regression line
obtained from the logarithm of PAS plasma
concentration vs time. Regression line:
y = mx + b, where m = slope and b = y
intercept.
Liver function tests and creatinine.-In
volunteers and patients, analysis of lactic
dehydrogenase (LDH), alkaline phosphatase
(AP), serum glutamic oxaloacetic trans-
aminase (SGOT), serum glutamic pyruvic
transaminase (SGPT), total bilirubin, total
serum proteins, serum albumin and creat-
inine was performed by our biochemistry
service, according to standard methods.
Statistical analysi8.-Significance of the
difference between volunteers and patients
of Groups II and III was assessed by
Student's t test and a P value of 0-05 or
less was considered significant.
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FIG. 1. Disappearance curve ofp-aminosalicylate (PAS) from the plasma of volunteers or patients
given a single 2-g oral dose of PAS. Each point represents the mean of 9 volunteers (Group I),
14 sensitive patients (Group II) and 7 resistant patients (Group III). Vertical bars represent
standard errors.
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shown in Fig. 2. Plasma half-life (T1/2)
of PAS was then estimated for the 3
groups. T112 does not differ between
sensitive and resistant patients, as also
demonstrated by the values (m) of the
slope. But compared with volunteers,
T1/2 of PAS in the patients is slightly
prolonged.
Reverse curves were obtained with
PAS conjugation (Fig. 3). Resistant pa-
tients (Group III) acetylated PAS to a
much greater extent than volunteers
or sensitive patients. In Group III, we
observed an increase in APAS, up to
75% oftotal plasma PAS, while volunteers
and sensitive patients did not acetylate
more than 50% of PAS.
30 60 120
Group I: m = -0-004690; b 1-755;
r = -0 9996
Group II: m = -0-003952; b 1-750;
r = - 09965
Group III: m = -0-004024; b = 1*495;
r = - 0-9851
FIG. 2.-Plasma half-life (T1/2) of PAS in
volunteers (Group I), sensitive patients
(Group II) and resistant patients (Group
III). T1/2 was calculated from the re-
gression line obtained from the logarithm of
PASplasmaconcentration versustime. The
correlation coefficients (r) are significant.
RESULTS
The plasma disappearance curves of
unchanged para-aminosalicylate (PAS)
after a single oral dose of PAS are pre-
sented in Fig. 1. In the volunteer and
patient groups, the peak plasma con-
centration of PAS is reached 30 min
after drug administration. Judging by
the low PAS plasma concentration ob-
served at 10 min, the gastrointestinal
absorption of PAS seems to be delayed
in all cancer patients, sensitive or re-
sistant to chemotherapy. But the PAS
concentration continues lower in resistant
patients (Group III) when there is no
significant difference between sensitive
patients (Group II) and volunteers (Group
I).
From the preceding data, regression
lines were calculated, and plotted as
TABLE I.-PAS and APAS in Total
Urine of Volunteers (Group I), Sensitive
Patients (Group II) and Resistant Pa-
tients (Group III), at 120 min Following
aSingle 2-g Oral Dose ofPAS
PAS APAS
(mg) (%)
Mean±s.e. Mean±s.e.
GroupI 331-3+26-3 56-4±4-2
Group II 291-7±38-5 54-9±3-2
Group III 97-6±12-7 71-4±3-3
II V8 I
III V8 I
NS* NS*
P<0.05 P<0.05
* NS = not significant.
TABLE II.-Abnormal Liver Functions and
Creatinine
Functions
* Group II LDH
AP
SGOT
SGPT
Total serum
proteins
t Group III LDH
SGOT
SGPT
Total serum
proteins
Serum
albumin
Creatinine
Number (and initials)
of patients having
abnormal values
2 (J.F.) (L-P.F.)
1 (L-P.F.)
1 (J.F.)
1 (J.F.)
5 (A.C.) (F.L.) (M.M.)
(A.G.) ( A.D.)
2
1
1
2
(D.L.) (L.G.)
(L.G.)
(L.G.)
(D-L.) (C.T.)
3 (D.L.) (L.G.) (C.T.)
2 (D.L.) (C.T.)
* Tests in 14 sensitive patients.
t Tests in 4 resistant patients.
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FIG. 3. Percentage of N-acetyl-p-aminosalicylate (APAS) recovered in plasma, from 10 to 120 min following a single 2-g oral dose ofPAS. Each point represents the mean of 9 volunteers (Group I), 14 sensitive patients (Group II) and 7 resistant patients (Group III). Vertical bars represent
standard errors.
In urine collected at 120 min after
drug administration, there is no significant
difference for PAS and APAS between
Groups I and II (Table I). But, as in
plasma, there is less PAS and more APAS
in Group III than in volunteers.
Finally,standardtestsforliverfunction
and creatinine were done in volunteers
and patients (Table II). All volunteers
had normal values. Seven out of 14
in Group II had moderately abnormal
functions (often evidenced in only one
test), while out of 4 Group III patients
tested, 3 or 4 abnormal functions were
observed in 3 patients.
DISCUSSION
The present investigation was under-
taken to study the role of certain host
factors such as drug distribution and
metabolism in clinical resistance to cancer
chemotherapy. As suggested by Connors
(1974) and Dedrick et al. (1975), host
effects might explain the ineffectiveness
of certain drugs in the treatment of
cancer: diminished absorption from site
of administration, poor transport to the
tumour, decreased biotransformation by
the liver, leading to a diminution in
active cytotoxic metabolites of certain
drugs like cyclophosphamide, cytarabine
and mercaptopurine (Chabner et al., 1975).
We decided to measure p-aminosali-
cylate (PAS) metabolism for two reasons.
First, the presence of cancer modifies
the pharmacokinetics of many drugs,
antineoplastic (Kato et al., 1968b; Barto-
sek et al., 1973; Benjamin, 1974; Bartosek
et al., 1975; Lavigne et al., 1975; Donelli et
al., 1976) as well as other (Kato, Takanaka
and Oshima, 1968a; Rosso, Dolfini and
Donelli, 1968; Franchi and Rosso, 1969;
Rosso et al., 1971; Basu, Parke and
-1-
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Williams, 1974a; Sharma and Garb, 1974;
Beck, Mandel and Fabro, 1975; Nadeau
and Marchand, 1975; Marchand and
Nadeau, 1976). Second, some metabolic
properties of PAS (Way et al., 1948;
Wan et al., 1974) such as short plasma
half-life, predominantly renal excretion
and the absence of side-effects at the
dose used (Weinstein, 1975) make it an
interesting model drug.
In healthy volunteers (Group I) the
plasma peak concentration of sodium
PAS (Fig. 1) and the plasma half-life
(Fig. 2) are comparable with reported
values (Way et al., 1948; Lavigne and
Marchand, 1973; Wan et al., 1974;
Weinstein, 1975). The PAS concentra-
tions (Fig. 1) in plasma of patients
(Groups II and III) are lower at 10 min
than those of volunteers, and seem to
indicate a delay in gastrointestinal ab-
sorption of PAS. Similar observations
were made with sulphacetamide in rats
bearing solid tumour (Nadeau and Mar-
chand, 1975) and in L1210 leukaemic
mice (MarchandandNadeau, 1976). Many
factors could be responsible for impaired
drug absorption, such as decreased muco-
sal blood flow to the intestine and slowing
in gastric emptying (Levine, 1970), necro-
sis and leukaemic infiltration of the
gastrointestinal tract (Matis, 1974), and
occlusion of the small intestine (Gardais,
Francois and Ronceray, 1976).
The slightly prolonged plasma half-life
of PAS in patients suffering from malig-
nant blood disease is not surprising
(Fig. 2). The disappearance rate of
carisoprodol (Kato et al., 1968a), pento-
barbital (Rosso et al., 1971; Beck et al.,
1975), adriamycin (Benjamin, 1974), sul-
phacetamide (Nadeau and Marchand,
1975) and cyclophosphamide (Donelli et
al., 1976) from the plasma of cancer
animals or patients was slower than that
of controls. For these drugs, prolonged
plasma half-life was usually explained
by decreased drug-metabolizing activity in
liver enzymes.
In the present experiments, we ob-
served a significant increase of PAS
acetylation (Fig. 3) in Group III patients.
N-acetyl-p-aminosalicylic acid (APAS) is
the principal metabolite of PAS (Way et
al., 1948; Wan et al., 1974) and this
conjugation of PAS with acetyl radical
leads to an inactive product, as happens
in most Phase II drugreactions (Bousquet,
1970). The high percentage of APAS
might therefore be correlated with the
low plasma level of unchanged active
PAS in the plasma of Group III (Fig. 1).
We may argue that the enhanced cata-
bolism of PAS, although unexplained,
is as noxious to our Group III patients
as the known decreased hepatic activation
of some antineoplastic drugs is to tumour-
bearing animals (Kato et al., 1968b;
Bartosek et al., 1975; Donelli et al.,
1976). It is known that antineoplastic
agents are activated into cytotoxic meta-
bolites or inactivated into degradation
products mainly by the Phase I drug
reactions (oxidation, reduction, hydro-
lysis). However, adrenocortical steroids
are conjugated with sulphate or with
glucuronic acid, and 6-mercaptopurine
undergoes a methylation (conjugation) to
give 6-MMP (Calabresi and Parks, 1975;
Chabner et al., 1975).
In urine collected at 120 min following
drug administration (Table I), the per-
centage of PAS conjugated to APAS in
Group I as well as the percentage (about
20) of the dose of excreted PAS are
similar to those reported by Way et al.
(1948), for healthy volunteers. Impaired
excretion of PAS in Group III is possible,
but is difficult to assess, because the
5% of the dose excreted after 120 min
may be explained by the low plasma
concentrations of PAS (Fig. 1) compared
with volunteers. The slightly prolonged
plasma half-life of PAS cannot explain a
slower renal clearance, because Group II,
who also have a slightly prolonged half-
life, excrete PAS as well as volunteers do.
We must stress that our subjects were
volunteers or patients of either sex,
young and old. As far as the curves
of plasma disappearance of PAS, acetyla-
tion and renal excretion are concerned,
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age and sex did not seem to have any
effect, contrary to what is reported in
the literature for many drugs (Bousquet,
1970; Triggs and Nation, 1975). But,
in agreement with the study of Kamp-
mann, Sinding and Jorgensen (1975), we
did not find any effect of age on liver
functions. In Group II (Table II), only
2 sensitive patients had 2 or 3 moderately
abnormal liver functions, and 5 of these
patients have only slightly low total
serum proteins (5a3-5*7%o). Inthisgroup,
one patient suffering from lymphosarcoma
had an elevated level of alkaline phos-
phatase, an enzyme whose elevation cor-
relates well with this disease (Belliveau,
Wiernik and Abt, 1974). Finally, the
higher frequency of abnormal liver func-
tion in Group III must be pointed out.
The far-advanced malignant disease is
probably more responsible than the che-
motherapy for the impaired liver func-
tions. Such findings were reported earlier
in patients with advanced non-hepatic
cancer (Basu, Raven and Williams, 1974b)
and it is also known that hepatic failure
is a cause of death in leukaemia (Chang et
al., 1976). The fact that 3 out of 4
resistant patients have low serum albumin
is interesting because, as mentioned by
Wilkinson and Schenker (1975), depressed
serum albumin level and/or prolonged
prothrombin time have provided the only
significant correlations between biochemi-
cal assessment of liver function and drug
disposition. Hypoalbuminaemia may ac-
count for a possible diminution ofalbumin
binding of drugs, and the smaller the
extent of albumin binding, the more
drug will be available for hepatic bio-
transformation (Koch-Weser and Sellers,
1976). The significant increase in PAS
acetylation (Group III) might in part
be so explained. It is also important
to note that 2/4 resistant patients had
elevated creatinine levels. But even if
renal complications may occur in leuk-
aemia and lymphomas (Frei et al., 1963),
a definite correlation with PAS excretion
cannot be made.
To summarize our results, malignant
blood diseases did not seem greatly to
influence PAS metabolism in sensitive
patients. However, in cancer patients
resistant to chemotherapy, we think that
changes in PAS absorption, fate and
excretion might reflect, by analogy,
changes in antineoplastic drug meta-
bolism. Of course, in these patients it
may be hard to dissociate resistance
to chemotherapy from the advanced
stage of the disease. As mentioned
earlier, these patients died shortly (30-90
days) after our study and moreover,
as demonstrated in tumour-bearing ani-
mals (Kato et al., 1968a, b; Rosso et al.,
1968; Franchi and Rosso, 1969; Rosso et
al., 1971; Basu et at., 1974a; Beck et
al., 1975; Lavigne et al., 1975) drug
metabolism and action were progressively
modified as a function oftumour growth.
This investigation was supported by
the Medical Research Council of Canada
(Grant No. MA-5561).
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